Literature DB >> 22250850

Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database.

S L Carpenter1, J Michael Soucie, S Sterner, R Presley.   

Abstract

Neutralizing inhibitors develop in 20-30% of patients with severe factor VIII (FVIII) deficiency. It is well established that Blacks have a higher prevalence of inhibitors than Whites. This is the first study to definitively demonstrate increased inhibitor prevalence in the Hispanic population. We compared inhibitor prevalence among various racial and ethnic groups in a cross-sectional analysis of 5651 males with severe haemophilia A that participated in the Universal Data Collection project sponsored by the Centers for Disease Control and Prevention. We used logistic regression analysis to control for potential confounding variables. We assigned as Hispanic those participants who were white and labelled themselves Hispanic. The prevalence of high-titre inhibitors in the Hispanic participants was 24.5% compared to 16.4% for White non-Hispanic patients (OR 1.4, 95% CI 1.1, 1.7). Possibilities as to the underlying cause of increased inhibitor prevalence in minority ethnic populations include polymorphisms in the FVIII molecule, HLA subtypes and differing inflammatory responses. A better understanding may lead to tailored treatment programmes, or other therapies, to decrease or prevent inhibitor development.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22250850     DOI: 10.1111/j.1365-2516.2011.02739.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  11 in total

1.  Game, set, match for factor VIII mismatch?

Authors:  Connie H Miller
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

2.  Men with severe hemophilia in the United States: birth cohort analysis of a large national database.

Authors:  Marshall A Mazepa; Paul E Monahan; Judith R Baker; Brenda K Riske; J Michael Soucie
Journal:  Blood       Date:  2016-03-16       Impact factor: 22.113

3.  The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients.

Authors:  Patricia Pinto; Tejashree Shelar; Vidhya Nawadkar; Darshana Mirgal; Alfiya Mukaddam; Preethi Nair; Priyanka Kasatkar; Tejasvita Gaikwad; Shahnaz Ali; Anshul Jadli; Rucha Patil; Anita Parihar; Sharda Shanbhag; Bipin Kulkarni; Kanjaksha Ghosh; Shrimati Shetty
Journal:  Indian J Hematol Blood Transfus       Date:  2014-02-05       Impact factor: 0.900

4.  Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database.

Authors:  J Puetz; J M Soucie; C L Kempton; P E Monahan
Journal:  Haemophilia       Date:  2013-07-16       Impact factor: 4.287

Review 5.  FVIII inhibitors: pathogenesis and avoidance.

Authors:  Jan Astermark
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

6.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

7.  The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.

Authors:  B M Reipert; B Gangadharan; C J Hofbauer; V Berg; H Schweiger; J Bowen; J Blatny; K Fijnvandraat; E S Mullins; J Klintman; C Male; C McGuinn; S L Meeks; V C Radulescu; M V Ragni; M Recht; A D Shapiro; J M Staber; H M Yaish; E Santagostino; D L Brown
Journal:  Blood Adv       Date:  2020-11-24

8.  The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.

Authors:  Tarek Owaidah; Abdulkareem Al Momen; Hazzaa Alzahrani; Abdulrahman Almusa; Fawaz Alkasim; Ahmed Tarawah; Randa Al Nouno; Fatima Al Batniji; Fahad Alothman; Ali Alomari; Saud Abu-Herbish; Mahmoud Abu-Riash; Khawar Siddiqui; Mansor Ahmed; S Y Mohamed; Mahasen Saleh
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

9.  Mutational Profiles of F8 and F9 in a Cohort of Haemophilia A and Haemophilia B Patients in the Multi-ethnic Malaysian Population.

Authors:  Maimiza Zahari; Siti Aishah Sulaiman; Zulhabri Othman; Yasmin Ayob; Faraizah Abd Karim; Rahman Jamal
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

10.  Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services.

Authors:  Raida Oudat; Muna Al-Maharmeh; Rasha Al-Ghrayeb; Tunia Ogeilat; Maher Kh Mustafa
Journal:  Med Arch       Date:  2020-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.